# CVD 909 Vi Prime Boost Study

> **NCT00326443** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 21 (actual)

## Conditions studied

- Typhoid Fever

## Interventions

- **BIOLOGICAL:** CVD 909
- **DRUG:** Placebo
- **BIOLOGICAL:** Vi Polysaccharide

## Key facts

- **NCT ID:** NCT00326443
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-09
- **Final completion:** 2008-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326443, "CVD 909 Vi Prime Boost Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00326443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*